RxDoctor Payments Data

Jenny Bodnar

Family · Hudson, OHNPI 1972054849

Payments from drug & device makers

$350in general payments, 2019–2025

Across 13 payments — averaging $26.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$125
  • Exact Sciences$60
  • Novo Nordisk$56
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$23
  • Astellas Pharma US Inc$22
  • AbbVie$21
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$350100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$350 in reported general payments places this provider in the 50th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$15,815
Medicare patients
124
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$40,014
JardianceEmpagliflozin33$26,024
OzempicSemaglutide21$20,465
JanuviaSitagliptin Phosphate20$18,817
Breo ElliptaFluticasone/Vilanterol12$4,697
Albuterol Sulfate HfaAlbuterol Sulfate76$1,779
Atorvastatin Calcium219$1,738
Duloxetine Hcl50$1,512
PaxlovidNirmatrelvir/Ritonavir16$1,429
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,327
Levothyroxine Sodium148$1,274
Losartan Potassium127$1,041
Omeprazole83$842
Gabapentin45$814
FenofibrateFenofibrate Nanocrystallized25$751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$56$20,46521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 6,812 family providers in Ohio.

Other family in Hudson

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →